Publications by authors named "Richard Messmann"

Claim this Profile
A
A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in Cancer.
Mark R Kelley, Jun Wan, Sheng Liu, Eyram Kpenu, Randall Wireman, Richard A Messmann

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer.
Mark R Kelley, Jun Wan, Sheng Liu, Eyram Kpenu, Randall Wireman, Richard A Messmann

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330.
Larissa L Silva, Robert E Stratford, Richard Messmann, Mark R Kelley, Sara K Quinney

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and pain outcomes with [Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Karim Fizazi, Ken Herrmann, Bernd J Krause, Kambiz Rahbar, Kim N Chi, Richard A Messmann

Lancet Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial.
Phillip H Kuo, Taylor Benson, Richard Messmann, Michael Groaning

J Nucl Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.
Wael Harb, Nehal J Lakhani, Richard Messmann, Barbara Klencke, Ayad M Al-Katib

Clin Lymphoma Myeloma Leuk· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor, Johann de Bono, Kim N Chi, Karim Fizazi, Ken Herrmann, Richard A Messmann

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease.
Rachel A Caston, Silpa Gampala, Lee Armstrong, Richard A Messmann, Melissa L Fishel

Drug Discov Today· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.
Ronald L Van Heertum, Robert Scarimbolo, John G Wolodzko, Barbara Klencke, Richard Messmann

Drug Des Devel Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.
Fenil Shah, Derek Logsdon, Richard A Messmann, Jill C Fehrenbacher, Melissa L Fishel

NPJ Precis Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.
Wendi V Rodrigueza, Michael J Woolliscroft, Abdul-Shukkur Ebrahim, Robert Forgey, Patrick J McGovren, Richard A Messmann

Cancer Chemother Pharmacol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
Anthony W Tolcher, Wendi V Rodrigueza, Drew W Rasco, Amita Patnaik, Kyriakos P Papadopoulos, Richard A Messmann

Cancer Chemother Pharmacol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
R Wendel Naumann, Robert L Coleman, Robert A Burger, Edward A Sausville, Elzbieta Kutarska, Richard A Messmann

J Clin Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Patricia M Lorusso, Martin J Edelman, Susan L Bever, Karen M Forman, Maryjo Pilat, Richard A Messmann

J Clin Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Martin J Edelman, Wael A Harb, Sridhar E Pal, Ralph V Boccia, Michael J Kraut, Richard A Messmann

J Thorac Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
Christopher P Leamon, Joseph A Reddy, Patrick J Klein, Iontcho R Vlahov, Ryan Dorton, Richard A Messmann

J Pharmacol Exp Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.
Jing Li, Edward A Sausville, Patrick J Klein, David Morgenstern, Christopher P Leamon, Richard A Messmann

J Clin Pharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.
Ronald E Fisher, Barry A Siegel, Steven L Edell, Nelson M Oyesiku, David E Morgenstern, Richard A Messmann

J Nucl Med· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Alex Sparreboom, Huachen Chen, Milin R Acharya, Adrian M Senderowicz, Richard A Messmann

Clin Cancer Res· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Suoping Zhai, Edward A Sausville, Adrian M Senderowicz, Yuichi Ando, Donna Headlee, Richard A Messmann

Anticancer Drugs· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Richard A Messmann, Claudio Dansky Ullmann, Tyler Lahusen, Audrey Kalehua, Jason Wasfy

Clin Cancer Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Antoinette R Tan, Donna Headlee, Richard Messmann, Edward A Sausville, Susan G Arbuck

J Clin Oncol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis